Elsevier partners with ExactCure to predict pharmacokinetics of repurposed drugs

16 April 2020 (Last Updated April 16th, 2020 17:40)

Information analytics company Elsevier is collaborating with AI start-up ExactCure to review approved drugs being repurposed for Covid-19 and simulate their pharmacokinetic properties in patients.

Elsevier will contribute its PharmaPendium database of FDA/EMA drug approval documents to allow ExactCure to model approximately 20 drugs, including hydroxychloroquine and azithromycin, and help to accelerate Covid-19 research.

Elsevier translational medicine solutions director Olivier Barberan explained: “As the pandemic deepens, hundreds of clinical trials have been set up to test existing medications against Covid-19.

“Elsevier has taken its work further by sharing PharmaPendium data to support ExactCure in building the ‘digital twin’ that simulates in-silico the efficacy and interactions of drugs in the body of a patient based on their personal characteristics.

"This can be extremely helpful for the clinical pharmacologists and frontline doctors in the development of safe and effective treatment. We are looking forward to continuing this work with ExactCure to help reduce the impact of this global pandemic.”